

World Congress on
Dementia, Alzheimer's, Parkinson's & Neurodegenerative Disorders
July 09-10, 2026 | Frankfurt, Germany



Victor Danelon¹, Nicholas C Morano^{2,3}, Sarah C Garrett-Thomson¹, Steven C Almo², Francis S Lee³, Barbara L Hempstead¹

1 Department of Medicine, Weill Cornell Graduate School of Medical Sciences, New York, New York, USA.

2 Department of Biochemistry, Albert Einstein College of Medicine, New York, New York, USA.

3 Zuckerman Mind Brain Behavior Institute, Columbia University, New York, New York, USA.

4 Department of Psychiatry, Weill Cornell Medicine, New York, New York, USA.

Human immunomodulatory ligand B7-1 mediates synaptic remodeling via the p75 neurotrophin receptor

Cell surface receptors, ligands, and adhesion molecules underlie development, circuit formation, and synaptic function of the central nervous system and represent important therapeutic targets for many neuropathologies. The functional contributions of interactions between cell surface proteins of neurons and nonneuronal cells have not been fully addressed. Using an unbiased protein-protein interaction screen, we showed that the human immunomodulatory ligand B7-1 (hB7-1) interacts with the p75 neurotrophin receptor (p75NTR) and that the B7-1:p75NTR interaction is a recent evolutionary adaptation present in humans and other primates, but absent in mice, rats, and other lower mammals. The surface of hB7-1 that engages p75NTR overlaps with the hB7-1 surface involved in CTLA-4/CD28 recognition, and these molecules directly compete for binding to p75NTR. Soluble or membrane-bound hB7-1 altered dendritic morphology of cultured hippocampal neurons, with loss of the postsynaptic protein PSD95 in a p75NTR-dependent manner. Abatacept, an FDA-approved therapeutic (CTLA-4-hFc fusion) inhibited these processes. In vivo injection of hB7-1 into the murine subiculum, a hippocampal region affected in Alzheimer's disease, resulted in p75NTR-dependent pruning of dendritic spines. Here, we report the biochemical interaction between B7-1 and p75NTR, describe biological effects on neuronal morphology, and identify a therapeutic opportunity for treatment of neuroinflammatory diseases.

Biography

Victor Danelon is a neuroscientist and biomedical researcher serving as a Research Associate in the Department of Medicine at Weill Cornell Medical College since 2022. His research focuses on the molecular and cellular mechanisms that regulate brain development, neuronal function, and neurodegenerative diseases. He earned his bachelor's degree in 2011 and a Ph.D. in Biological Sciences in 2016 from the National University of Córdoba, Argentina, where he developed expertise in molecular neuroscience, cell biology, advanced microscopy, and experimental models of neurological disorders.

Dr. Danelon has contributed to numerous peer-reviewed publications investigating topics such as brain-derived neurotrophic factor (BDNF) signaling, TrkB receptor biology, synaptic plasticity, dendritic morphogenesis, epilepsy-induced neuronal injury, and neuroprotection. By integrating molecular, cellular, and translational research approaches, his work advances the understanding of the biological mechanisms underlying neurological diseases and supports the development of potential therapeutic strategies for disorders affecting the nervous system.